At EuroPCR: Drug-Eluting Stents From Asia, But At What Cost?
No one would place drug-eluting stents among the hot technologies showcased at this year’s EuroPCR, not with all the buzz around renal denervation, percutaneous valves, and bioabsorbable stents and scaffolds. But an early morning session on DES from India and China underscored how the technology debate is changing in a world of cost constraints and emerging markets, particularly for mature categories.
You may also be interested in...
For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was a bit more balanced, leaving room for interest in bioresorbable stents and mitral valves.
Bioresorbable coronary scaffolds could transform the coronary stenting market once they become widely available. But although there are more than a dozen companies developing these promising devices, there are still a number of unanswered questions – chief among them, how effectively they will compete against existing and upcoming next-generation durable stents, and how much of a price premium bioresorbable devices will be able to command.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.